The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Left Ventricular Hypertrophy in the Renal Patient
Abstract
Pathophysiology Physiologically, left ventricular hypertrophy is primarily an adaptive remodeling process, compensating for an increase in workload placed on the heart with the aim of minimizing ventricular wall stress. Two contrasting models of adaptation may develop depending on the patterns of stress imposed. Pressure overload, caused, for example, by hypertension or aortic stenosis, requires the generation of greater intracavitary pressure during ventricular contraction. This is achieved by arraying contractile protein units in parallel. Relatively, an increase in wall thickness and a fall in cavity volume take place. Concentric hypertrophy, as this process is known, leads to decreased diastolic compliance and may place the myocardium at risk of ischemia, even without coronary artery disease. In conditions of volume overload, such as anemia or aortic incompetence, lengthening of contractile units leads to a physiologically useful increase in systolic stroke volume, according to Starling's Law. Unopposed, this process of left ventricular dilation leads to increased wall tension, a state known to increase oxygen requirements, and myocyte burnout. According to the Law of Laplace, the wall tension of a hollow spherical body is directly proportional to radius and pressure and inversely proportional to wall thickness. Thus, in states of left ventricular dilation, wall thickening and left ventricular hypertrophy are useful secondary order adaptations that tend to decrease wall tension. The molecular mechanisms that underlie these processes are slowly being unraveled. Subtle signaling changes can lead from physiologic adaptation to pathologic maladaptation. With continuing pressure and volume overload, cardiac myocyte apoptosis accelerates. In addition, fibrosis accelerates. Hypertrophy, apoptosis, and fibrosis are influenced by constitutional and genetic factors, hormones, growth factors, and cytokines such as endothelin 1, angiotensin II, insulin-like growth factor, and tumor necrosis factor α. The balance of these factors and downstream intracellular signals can alter the balance among hypertrophy, apoptosis, and fibrosis (1). Experimental Studies Experimental studies, especially the pioneering work from the Heidelberg group, have greatly advanced our understanding of the morphology and pathogenesis of uremic cardiomyopathy. The principal morphologic features are increased heart size, interstitial fibrosis, thickening of intramyocardial arterioles, and a reduction of capillary length density, so that there is a reduction in the ratio of perfusing capillaries to myocardium supplied (2). In these models, uremic cardiomyopathy is very much a “metabolic” condition, with little or no relationship to classic hemodynamic stresses, such as hypertension and anemia. Parathyroid hormone (3) is a permissive factor for these changes, which seem to be preventable by angiotensin-converting enzyme (ACE) inhibition (4), agents that reduce central sympathetic outflow (4) and endothelin antagonists (5). Hyperparathyroidism, by virtue of its effect as a calcium ionophore, is known to lead to intramyoctye calcium overload, altered bioenergetics, and relative ischemia (6). Bradykinin may also be a contributory factor to the preventive action of ACE inhibition (7). Immunohistochemical studies of signal transduction factors suggest that rates of apoptosis may accelerate during the development of uremic cardiomyopathy (8). Diagnosis and Classification Left ventricular hypertrophy is a histologic entity. Myocardial biopsy is rarely performed, so it is rarely possible in practice to prove that maladaptive pathologic features, especially fibrosis, are present. Instead, we rely on measures of left ventricular size, geometry, and function. Echocardiography is noninvasive and provides an accurate assessment of each of these parameters. For each parameter, superior techniques exist but are not routinely used because of expense, unavailability, or invasiveness. Thus, magnetic resonance imaging seems to be a superior technique to assess left ventricular mass and cavity volume in patients with end-stage renal disease (ESRD) (9). Similarly, cardiac function is measured better with invasive techniques. In practice, echocardiography is a reasonable overall tool and is highly suited to longitudinal research studies. Left ventricular mass is calculated by assuming that the ventricle is a hollow spheroid. In the general population, left ventricular mass increases with age, male gender, and body size. For comparative purposes, left ventricular mass usually is normalized to some index of body size. The ideal method remains a matter of debate. However, normalization to body surface area is the most commonly used method. In the healthy, adult, Framingham population, the upper limits of normal are 131 g/m2 for males and 100 g/m2 for females (10). Calculated mass index increases with extracellular fluid volume expansion. The calculated mass index has bee
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Koren, M. J., Devereux, R. B., Casale, P. N., Savage, D. D., & Laragh, J. H. (1991) · Annals of Internal Medicine · doi:10.7326/0003-4819-114-5-345 · Cited by 2,366
Block, G., Hulbert-Shearon, T., Levin, N., & Port, F. (1998) · American Journal of Kidney Diseases · doi:10.1053/ajkd.1998.v31.pm9531176 · Cited by 2,354
Accelerated Atherosclerosis in Prolonged Maintenance Hemodialysis
Lindner, A., Charra, B., Sherrard, D. J., & Scribner, B. H. (1974) · New England Journal of Medicine · doi:10.1056/nejm197403282901301 · Cited by 1,776
Clinical and echocardiographic disease in patients starting end-stage renal disease therapy
Foley, R. N., Parfrey, P. S., Harnett, J. D., Kent, G. M., Martin, C. J., Murray, D. C., & Barre, P. E. (1995) · Kidney International · doi:10.1038/ki.1995.22 · Cited by 1,299
Self-citationSignaling Pathways for Cardiac Hypertrophy and Failure
Hunter, J. J., & Chien, K. R. (1999) · New England Journal of Medicine · doi:10.1056/nejm199910213411706 · Cited by 869
Left ventricular mass index increase in early renal disease: Impact of decline in hemoglobin
Levin, A., Thompson, C. R., Ethier, J., Carlisle, E. J. F., Tobe, S., Mendelssohn, D., Burgess, E., Jindal, K., Barrett, B., Singer, J., et al. (1999) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(99)70118-6 · Cited by 841
Echocardiographic criteria for left ventricular hypertrophy: The Framingham heart study
Levy, D., Savage, D. D., Garrison, R. J., Anderson, K. M., Kannel, W. B., & Castelli, W. P. (1987) · The American Journal of Cardiology · doi:10.1016/0002-9149(87)91133-7 · Cited by 799
The impact of anemia on cardiomyopathy, morbidity, and mortality in end-stage renal disease
Foley, R. N., Parfrey, P. S., Harnett, J. D., Kent, G. M., Murray, D. C., & Barre, P. E. (1996) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(96)90130-4 · Cited by 769
Self-citationHematocrit Level and Associated Mortality in Hemodialysis Patients
MA, J. Z., EBBEN, J., XIA, H., & COLLINS, A. J. (1999) · Journal of the American Society of Nephrology · doi:10.1681/asn.v103610 · Cited by 577
Impact of hypertension on cardiomyopathy, morbidity and mortality in end-stage renal disease
Foley, R. N., Parfrey, P. S., Harnett, J. D., Kent, G. M., Murray, D. C., & Barre, P. E. (1996) · Kidney International · doi:10.1038/ki.1996.194 · Cited by 492
Self-citation
Cited by
FGF23 induces left ventricular hypertrophy
Faul, C., Amaral, A. P., Oskouei, B., Hu, M.-C., Sloan, A., Isakova, T., Gutiérrez, O. M., Aguillon-Prada, R., Lincoln, J., Hare, J. M., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci46122 · Cited by 2,027
Fibroblast Growth Factor 23 and Left Ventricular Hypertrophy in Chronic Kidney Disease
Gutiérrez, O. M., Januzzi, J. L., Isakova, T., Laliberte, K., Smith, K., Collerone, G., Sarwar, A., Hoffmann, U., Coglianese, E., Christenson, R., et al. (2009) · Circulation · doi:10.1161/circulationaha.108.844506 · Cited by 837
Endogenous Cardiotonic Steroids: Physiology, Pharmacology, and Novel Therapeutic Targets
Bagrov, A. Y., Shapiro, J. I., & Fedorova, O. V. (2009) · Pharmacological Reviews · doi:10.1124/pr.108.000711 · Cited by 532
Fibroblast Growth Factor-23 and Cardiovascular Events in CKD
Scialla, J. J., Xie, H., Rahman, M., Anderson, A. H., Isakova, T., Ojo, A., Zhang, X., Nessel, L., Hamano, T., Grunwald, J. E., et al. (2014) · Journal of the American Society of Nephrology · doi:10.1681/asn.2013050465 · Cited by 445
Himmelfarb, J., & Ikizler, T. A. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0902710 · Cited by 369
Metadata
- Authors
- MIDDLETON, R. J., PARFREY, P. S., & FOLEY, R. N.
- Venue
- Journal of the American Society of Nephrology
- Published
- 2001-05
- Volume
- 12
- Issue
- 5
- Pages
- 1079-1084
- ISSN
- 1046-6673 (ISSN-L)
- OpenAlex
- W2151617426
- Cited by
- 294
- References
- 40
- FWCI
- 6.35
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Left Ventricular Hypertrophy in the Renal Patient. https://app.cochat.ai/papers/10.1681/asn.v1251079
- The paper
- MIDDLETON, R. J., PARFREY, P. S., & FOLEY, R. N. (2001). Left Ventricular Hypertrophy in the Renal Patient. Journal of the American Society of Nephrology. https://doi.org/10.1681/asn.v1251079
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.